Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront Ruxolitinib Treatment for Chronic Graft-vs-host Disease in Children and Young Adults
NCT06695507Phase 1Terminated
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Overall Response Rate at 6 months. Started Feb 2025; status: terminated.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06695507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695507.